{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:05:40Z","timestamp":1785542740138,"version":"3.56.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["pericles.pericles-gcp.literatumonline.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2023,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine\/tipiracil (FTD\/TPI) in patients with metastatic colorectal cancer (mCRC) in a real\u2010world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression\u2010free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (&lt;3 metastatic sites at inclusion, \u226518\u2009months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC\/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD\/TPI. Overall, median [95%\u2010CI] OS was 7.4\u2009months [6.4\u20108.6], median PFS was 2.9\u2009months [2.8\u20103.3]. In BPC (n\u2009=\u200965) and GPC (n\u2009=\u2009176) compared to PPC (n\u2009=\u2009124) subgroup, median OS (13.3 [9.1\u201017.6] vs 8.9 [7.6\u20109.8] vs 5.1 [4.4\u20107.0] months) and median PFS (4.0 [3.3\u20105.3] vs 3.4 [3.0\u20103.7] vs 2.6 [2.4\u20102.8] months) were longer. Patient\u2010reported QoL, assessed by validated questionnaires (EQ\u20105D\u20105L, PRO\u2010CTCAE), was stable throughout FTD\/TPI treatment. Predominant FTD\/TPI\u2010related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD\/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health\u2010related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD\/TPI, highlighting its value in routine clinical practice.<\/jats:p>","DOI":"10.1002\/ijc.34603","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:45:01Z","timestamp":1685627101000},"page":"1227-1240","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness, safety and <scp>quality of life<\/scp> of trifluridine\/tipiracil in pretreated patients with metastatic colorectal cancer: Real\u2010world data from the noninterventional <scp>TACTIC<\/scp> study in Germany"],"prefix":"10.1002","volume":"153","author":[{"given":"Hendrik","family":"Kr\u00f6ning","sequence":"first","affiliation":[{"name":"Schwerpunktpraxis f\u00fcr H\u00e4matologie und Onkologie  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"G\u00f6hler","sequence":"additional","affiliation":[{"name":"Onkozentrum Dresden\/Freiberg  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[{"name":"Studienzentrum Onkologie Ravensburg  Ravensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Grundeis","sequence":"additional","affiliation":[{"name":"Onkologische Gemeinschaftspraxis Dr. med. Grundeis, Dr. med. Teich  Chemnitz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Kojouharoff","sequence":"additional","affiliation":[{"name":"Onkologische Schwerpunktpraxis Darmstadt  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Lipke","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis f\u00fcr H\u00e4matologie und Onkologie  Dortmund Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Semsek","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr interdisziplin\u00e4re Onkologie, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Moorahrend","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr H\u00e4matologie und Onkologie MVZ GmbH  Porta Westfalica Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauer","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum f\u00fcr Blut\u2010und Krebserkrankungen  Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald\u2010Robert","family":"Bruch","sequence":"additional","affiliation":[{"name":"Praxiskooperation Bonn\u2014Euskirchen\u2010Rheinbach\u2014Wesseling  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Liersch","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis f\u00fcr H\u00e4matologie und Onkologie  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Nusch","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr H\u00e4matologie und internistische Onkologie  Ratingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Vehling\u2010Kaiser","sequence":"additional","affiliation":[{"name":"\u00dcBAG MVZ Dr. Vehling\u2010Kaiser GmbH  Landshut Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"MVZ am Klinikum Aschaffenburg  Aschaffenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Centrum f\u00fcr H\u00e4matologie und Onkologie Bethanien  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns\u2010Detlev","family":"Harich","sequence":"additional","affiliation":[{"name":"Onkologie Hof MVZ  Hof Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Stephany","sequence":"additional","affiliation":[{"name":"MVZ Onkologie am Elisabeth\u2010Krankenhaus Rheydt  M\u00f6nchengladbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Praxis Dr. med. Jens Uhlig  Naunhof Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"de Buhr","sequence":"additional","affiliation":[{"name":"iOMEDICO, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Frank","sequence":"additional","affiliation":[{"name":"iOMEDICO, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Hogrefe","sequence":"additional","affiliation":[{"name":"iOMEDICO, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Marschner","sequence":"additional","affiliation":[{"name":"iOMEDICO, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"iOMEDICO, Freiburg im Breisgau  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hartmann","sequence":"additional","affiliation":[{"name":"SERVIER Deutschland GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Reisl\u00e4nder","sequence":"additional","affiliation":[{"name":"SERVIER Deutschland GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-7282","authenticated-orcid":false,"given":"Ingo","family":"Schwaner","sequence":"additional","affiliation":[{"name":"Onkologische Schwerpunktpraxis Kurf\u00fcrstendamm  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i26.4675"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.04.007"},{"key":"e_1_2_12_6_1","unstructured":"Lonsurf\u2010epar\u2010product\u2010information_en.pdf [Internet]. Accessed February 4 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lonsurf\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy038"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70345-5"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.009"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000752"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw422"},{"key":"e_1_2_12_15_1","unstructured":"Multicenter study to evaluate the impact of eHealth monitoring on overall survival in patients with metastatic non\u2010squamous NSCLC or extensive\u2010stage SCLC or advanced TNBC under first\u2010line treatment with atezolizumab in combination with chemotherapy (CHAPLIN) [Internet]. Accessed November 2022.https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/awb\/nis\u20100401\u20100500\/0475\u2010abschlussb.pdf?__blob=publicationFile&v=1"},{"key":"e_1_2_12_16_1","unstructured":"EuroQol Group.EQ\u20105D\u20105L User Guide."},{"key":"e_1_2_12_17_1","unstructured":"Patient\u2010Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO\u2010CTCAE) [Internet]. Accessed February 7 2022.https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2639"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1196-z"},{"key":"e_1_2_12_21_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. PublishedNovember 27 2017. U.S. Department of Health and Human Services.http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6475-6"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02130-x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1605192"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1238"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184514"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93732-5"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100391"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000698"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6533"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T20:23:30Z","timestamp":1693945410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9,15]]}},"alternative-id":["10.1002\/ijc.34603"],"URL":"https:\/\/doi.org\/10.1002\/ijc.34603","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}